Quarterly ResultJul 29, 2026, 06:11 AM
Dr. Reddy's Q1 Revenue $853M, down 5.6%; Semaglutide impacts EBITDA
AI Summary
Dr. Reddy's Laboratories reported Q1 FY27 consolidated revenues of $853 million, a 5.6% year-over-year decline, primarily due to lower lenalidomide sales and a $28 million provision for semaglutide API challenges. The underlying base business, excluding lenalidomide, showed healthy double-digit growth across key geographies. EBITDA margin was 12.5%, or 15.4% excluding the semaglutide provision. The company expects semaglutide supplies to resume by November and remains confident in a strong second half of the fiscal year.
Key Highlights
- Consolidated revenue declined 5.6% YoY to $853 million (₹8,071 crores).
- EBITDA margin was 12.5%, or 15.4% excluding semaglutide API provision.
- Semaglutide API challenges led to a ₹240 crores ($28 million) provision.
- North America Generics revenue was $236 million, down 41% YoY due to lenalidomide.
- India business grew 17% YoY to ₹1,718 crores, with 15.5% organic growth.
- USFDA issued 7 observations at Bachupally biologics facility; responses submitted.
- Abatacept BLA goal date remains December 2026.
- Net cash surplus stood at ₹3,057 crores ($323 million).
Price Impact
More from RDY